Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050582 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
A Phase 4 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
NCT01050582 is a Phase 4 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 244 participants.
The verdict
NCT01050582, a Phase 4 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.
Interventions
- DRUG Risperidone
- DRUG Other atypical antipsychotic drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050582
The ClinicalTrials.gov registry entry for NCT01050582 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT01050582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01050582 about?
NCT01050582 is a clinical study titled "A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children". The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.
What is the current status of trial NCT01050582?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2009-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01050582?
The interventions under investigation include: Risperidone (DRUG), Other atypical antipsychotic drugs (DRUG).
Who is sponsoring clinical trial NCT01050582?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.